Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Outset Medical Q3 2026 Results: Net Loss of $14.7M, Loss Narrows

Outset Medical reported total revenue of $33.6 million for the third quarter of 2026, an increase from $29.4 million in the prior year period. The company reduced its quarterly net loss to $14.7 million compared to $17.8 million in Q3 2025, driven by improved gross margins and lower operating expenses.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue33.629.4
Gross profit13.711.6
Profit before tax-14.5-17.4
Net income-14.7-17.8
EPS (diluted, $ a share)$-0.78$-1.00

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+14.2%
Gross margin40.7%
Operating margin-36.5%
Source

10-Q filed with the SEC, NASDAQ: OM. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Outset Medical, Inc.: key numbers

Share price
$3.39Close, Nov 16
Market cap
$64M
Shares outstanding
18.87MLatest SEC cover page
Sector
Industrial Applications and Services
Industry
Electromedical & Electrotherapeutic ApparatusSIC 3845

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Outset Medical, Inc.

All →
4:17 PM ET 8-K
Financial Results

Outset Medical Financial Results

Outset Medical reported third quarter 2026 revenue of $33.6 million, a 14% increase year-over-year, driven by strong growth in console and recurring revenue. The company reduced its net loss to $14.7 million from $17.8 million in the prior-year period while expanding gross margins to 40.7%. Management reiterated its full-year 2026 revenue guidance of $125 million to $130 million.

Term
Q3 2026

“Third-quarter results demonstrated continued progress against our strategic priorities and solid sales execution across both capital and recurring revenue. Consistently strong customer satisfaction and retention are expanding adoption of Tablo across our existing customer base and fueling new insourced dialysis partnerships with leading health systems. Advancing our mission to help providers nationwide improve the cost, complexity and clinical outcomes of dialysis continues to position Outset well for sustained long-term growth and value creation.”

Leslie Trigg, Chair and Chief Executive Officer
7:25 PM ET Form 4
Insider Buying

Outset Medical 10% Owner Braden Michael Leonard Buys $870K of Stock

Braden Michael Leonard, 10% Owner, bought 244,909 shares of Outset Medical, Inc. at $3.53 to $3.88 a share (average $3.55) in 2 transactions, worth $870K in total between Oct 1, 2026 and Oct 2, 2026. Shares held after the trade: 2,764,610 (+0.6%).

Value
$870K
Shares
244,909
Average price
$3.55
Role
10% Owner
Holding change
+0.6%
Trade date
Oct 1, 2026 to Oct 2, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.